IRVINE, Calif., May 11, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Ocwen Financial Corporation (“Ocwen” or the “Company”) (NYSE:OCN). Investors who purchased or otherwise acquired shares between May 11, 2015 and April 19, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the June 20, 2017 lead plaintiff motion deadline.
If you purchased Ocwen shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Ocwen made false and/or misleading statements and/or failed to disclose: that the Company engaged in significant and systemic misconduct at nearly every stage of the mortgage servicing process; that this conduct would subject Ocwen to heightened regulatory scrutiny and potential criminal sanctions; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On April 20, 2017, the U.S. Consumer Financial Protection Bureau announced that it was suing Ocwen, and several states issued cease-and-desist orders against the Company. Following this news, Ocwen’s stock price decreased materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 



